Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection

키워드

참고문헌 (95)

1. May AK, "Surgical Infection Society. Treatment of complicated skin and soft tissue infections", Surg Infect (Larchmt), 10, pp.467~499 (2009)
2. Esposito S, "Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy", J Chemother, 23, pp.251~262 (2011)
3. 최성호, "연부조직 감염 진료지침 권고안", Infection and Chemotherapy, 44(4), pp.213~232 (2012), 대한감염학회
4. Stevens DL, "Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.e10~e52 (2014)
5. Sartelli M, "World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections", World J Emerg Surg, 9, pp.57~ (2014)
6. Japanese Society of Chemotherapy Committee on guidelines for treatment of anaerobic infections, "Anaerobic infections (individual fields): skin and soft tissue infections", J Infect Chemother, 17(Suppl 1), pp.72~76 (2011)
7. Guyatt GH, "GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
8. Pasternack MS, "Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases", pp.1194~1215 (2015), Churchill Livingstone
9. Durupt F, "Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo", Br J Dermatol, 157, pp.1161~1167 (2007)
10. Hirschmann JV., "Impetigo: etiology and therapy", Curr Clin Top Infect Dis, pp.42~51 (2002)
11. Koning S, "Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double‐blind multicentre placebo‐controlled trial", Br J Dermatol, 158, pp.1077~1082 (2008)
12. Koning S, "Interventions for impetigo", Cochrane Database Syst Rev, 1, pp.CD003261~ (2012)
13. Wasserzug O, "A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes", Clin Infect Dis, 48, pp.1213~1219 (2009)
14. 배은영, "농가진의 원인 균주와 항생제 감수성에 관한 연구", 대한피부과학회지, 41(10), pp.1278~1285 (2003), 대한피부과학회
15. 김우중, "농가진의 원인 균주 및 항생제 감수성에 관한 연구", 대한피부과학회지, 50(9), pp.788~794 (2012), 대한피부과학회
16. Moran GJ, "Methicillin-resistant S. aureus infections among patients in the emergency department", N Engl J Med, 355, pp.666~674 (2006)
17. Rahimian J, "Does nasal colonization or mupirocin treatment affect recurrence of methicillin- resistant Staphylococcus aureus skin and skin structure infections?", Infect Control Hosp Epidemiol, 28, pp.1415~1416 (2007)
18. Ellis MW, "Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial", Antimicrob Agents Chemother, 51, pp.3591~3598 (2007)
19. Whitman TJ, "Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster- randomized, double-blind, controlled effectiveness trial", Infect Control Hosp Epidemiol, 31, pp.1207~1215 (2010)
20. Wiese-Posselt M, "Successful termination of a furunculosis outbreak due to lukS-lukF–positive, methicillin- susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005", Clin Infect Dis, 44, pp.e88~e95 (2007)
21. Fritz SA, "Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial", Clin Infect Dis, 54, pp.743~751 (2011)
22. Bisno AL, "Streptococcal infections of skin and soft tissues", N Engl J Med, 334, pp.240~245 (1996)
23. Perl B, "Cost-effectiveness of blood cultures for adult patients with cellulitis", Clin Infect Dis, 29, pp.1483~1488 (1999)
24. Hook EW 3rd, "Microbiologic evaluation of cutaneous cellulitis in adults", Arch Intern Med, 146, pp.295~297 (1986)
25. Kielhofner MA, "Influence of underlying disease process on the utility of cellulitis needle aspirates", Arch Intern Med, 148, pp.2451~2452 (1988)
26. Duvanel T, "Quantitative cultures of biopsy specimens from cutaneous cellulitis", Arch Intern Med, 149, pp.293~296 (1989)
27. Eriksson B, "Erysipelas: clinical and bacteriologic spectrum and serological aspects", Clin Infect Dis, 23, pp.1091~1098 (1996)
28. 곽이경, "단독과 연조직염의 임상적 특성과 원인균에 관한 연구", Infection and Chemotherapy, 44(2), pp.45~50 (2012), 대한감염학회[DOI]
29. Stevens DL, "Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections", Clin Infect Dis, 41, pp.1373~1406 (2005)
30. Bernard P, "Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique", Arch Dermatol, 125, pp.779~782 (1989)
31. "Int J Antimicrob Agents", 2017, S75~
32. Chan JC, "Ampicillin", sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology, 1995, pp.12, 139~146
33. Jeng A, "The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation", Medicine (Baltimore), 89, pp.217~226 (2010)
34. Hepburn MJ, "Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis", Arch Intern Med, 164, pp.1669~1674 (2004)
35. Dupuy A, "Risk factors for erysipelas of the leg (cellulitis): case-control study", BMJ, 318, pp.1591~1594 (1999)
36. Björnsdóttir S, "Risk factors for acute cellulitis of the lower limb: a prospective case-control study", Clin Infect Dis, 41, pp.1416~1422 (2005)
37. Jorup-Rönström C, "Recurrent erysipelas: predisposing factors and costs of prophylaxis", Infection, 15, pp.105~106 (1987)
38. McNamara DR, "A predictive model of recurrent lower extremity cellulitis in a population-based cohort", Arch Intern Med, 167, pp.709~715 (2007)
39. Lewis SD, "Risk factors for recurrent lower extremity cellulitis in a U.S. Veterans Medical Center population", Am J Med Sci, 332, pp.304~307 (2006)
40. Karppelin M, "Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study", Clin Microbiol Infect, 16, pp.729~734 (2010)
41. Pavlotsky F, "Recurrent erysipelas: risk factors", J Dtsch Dermatol Ges, 2, pp.89~95 (2004)
42. Sjöblom AC, "Antibiotic prophylaxis in recurrent erysipelas", Infection, 21, pp.390~393 (1993)
43. Kremer M, "Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections", J Infect, 22, pp.37~40 (1991)
44. UK Dermatology Clinical Trials Network’s PATCH Trial Team, "Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network’s PATCH II trial", Br J Dermatol, 166, pp.169~178 (2012)
45. Thomas KS, "U.K. Dermatology Clinical Trials Network’s PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis", N Engl J Med, 368, pp.1695~1703 (2013)
46. Wang JH, "Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs", Clin Infect Dis, 25, pp.685~689 (1997)
47. 최성호, "지역사회 획득 괴사성 근막염의 임상적 특성과 원인균에 관한 연구", Infection and Chemotherapy, 44(3), pp.180~184 (2012), 대한감염학회[DOI]
48. "Int J Antimicrob Agents", 2017, S136~
49. Wang YS, "Staging of necrotizing fasciitis based on the evolving cutaneous features", Int J Dermatol, 46, pp.1036~1041 (2007)
50. Schmid MR, "Differentiation of necrotizing fasciitis and cellulitis using MR imaging", AJR Am J Roentgenol, 170, pp.615~620 (1998)
51. Becker M, "Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management", Radiology, 202, pp.471~476 (1997)
52. Arslan A, "Necrotizing fasciitis: unreliable MRI findings in the preoperative diagnosis", Eur J Radiol, 36, pp.139~143 (2000)
53. Kao LS, "Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study", Am J Surg, 202, pp.139~145 (2011)
54. Zimbelman J, "Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection", Pediatr Infect Dis J, 18, pp.1096~1100 (1999)
55. Mulla ZD, "Invasive group A streptococcal infections in Florida", South Med J, 96, pp.968~973 (2003)
56. Ardanuy C, "Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008)", J Antimicrob Chemother, 65, pp.634~643 (2010)
57. Wong CH, "Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality", J Bone Joint Surg Am, 85-A, pp.1454~1460 (2003)
58. Elliott DC, "Necrotizing soft tissue infections. Risk factors for mortality and strategies for management", Ann Surg, 224, pp.672~683 (1996)
59. Voros D, "Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection", Br J Surg, 80, pp.1190~1191 (1993)
60. Darabi K, "Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature", Transfusion, 46, pp.741~753 (2006)
61. Kaul R, "Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-- a comparative observational study. The Canadian Streptococcal Study Group", Clin Infect Dis, 28, pp.800~807 (1999)
62. Norrby-Teglund A, "Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections", Scand J Infect Dis, 35, pp.683~689 (2003)
63. Darenberg J, "StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial", Clin Infect Dis, 37, pp.333~340 (2003)
64. "Int J Antimicrob Agents", 2017, S136~
65. Yu JS, "MR imaging of urgent inflammatory and infectious conditions affecting the soft tissues of the musculoskeletal system", Emerg Radiol, 16, pp.267~276 (2009)
66. Turecki MB, "Imaging of musculoskeletal soft tissue infections", Skeletal Radiol, 39, pp.957~971 (2010)
67. Crum NF, "Bacterial pyomyositis in the United States", Am J Med, 117, pp.420~428 (2004)
68. Chiu SK, "Impact of underlying diseases on the clinical characteristics and outcome of primary pyomyositis", J Microbiol Immunol Infect, 41, pp.286~293 (2008)
69. Faraklas I, "Development and validation of a necrotizing soft-tissue infection mortality risk calculator using NSQIP", J Am Coll Surg, 217, pp.153~160 (2013)
70. Bryant AE, "Clostridial myonecrosis: new insights in pathogenesis and management", Curr Infect Dis Rep, 12, pp.383~391 (2010)
71. Stevens DL, "Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens", J Infect Dis, 155, pp.220~228 (1987)
72. Stevens DL, "Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens", Antimicrob Agents Chemother, 31, pp.312~316 (1987)
73. Broder J, "Low risk of infection in selected human bites treated without antibiotics", Am J Emerg Med, 22, pp.10~13 (2004)
74. Medeiros I, "Antibiotic prophylaxis for mammalian bites", Cochrane Database Syst Rev, pp.CD001738~ (2001)
75. Zubowicz VN, "Management of early human bites of the hand: a prospective randomized study", Plast Reconstr Surg, 88, pp.111~114 (1991)
76. Cummings P, "Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials", Ann Emerg Med, 23, pp.535~540 (1994)
77. Callaham M, "Prophylactic antibiotics in common dog bite wounds: a controlled study", Ann Emerg Med, 9, pp.410~414 (1980)
78. Dire DJ, "Emergency management of dog and cat bite wounds", Emerg Med Clin North Am, 10, pp.719~736 (1992)
79. Elenbaas RM, "Prophylactic oxacillin in dog bite wounds", Ann Emerg Med, 11, pp.248~251 (1982)
80. Dire DJ, "Prophylactic oral antibiotics for low-risk dog bite wounds", Pediatr Emerg Care, 8, pp.194~199 (1992)
81. Abrahamian FM, "Microbiology of animal bite wound infections", Clin Microbiol Rev, 24, pp.231~246 (2011)
82. Goldstein EJ, "Bacteriology of human and animal bite wounds", J Clin Microbiol, 8, pp.667~672 (1978)
83. Goldstein EJ, "Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds", Antimicrob Agents Chemother, 32, pp.1143~1148 (1988)
84. Goldstein EJ, "Dog bite wounds and infection: a prospective clinical study", Ann Emerg Med, 9, pp.508~512 (1980)
85. Goldstein EJ, "Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida", Antimicrob Agents Chemother, 32, pp.213~215 (1988)
86. Stevens DL, "Antibiotic susceptibilities of human isolates of Pasteurella multocida", Antimicrob Agents Chemother, 16, pp.322~324 (1979)
87. Muguti GI, "Tetanus following human bite", Br J Plast Surg, 45, pp.614~615 (1992)
88. Talan DA, "Bacteriologic analysis of infected dog and cat bites", N Engl J Med, 340, pp.85~92 (1999), Emergency Medicine Animal Bite Infection Study Group
89. Kroger AT, "General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 55, pp.1~48 (2006)
90. "Guideline for rabies control 2017"[URL]
91. Rupprecht CE, "Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices", MMWR Recomm Rep, 59, pp.1~9 (2010)
92. Zook EG, "Successful treatment protocol for canine fang injuries", J Trauma, 20, pp.243~247 (1980)
93. Schultz RC, "The treatment of dog bite injuries, especially those of the face", Plast Reconstr Surg, 49, pp.494~500 (1972)
94. Chen E, "Primary closure of mammalian bites", Acad Emerg Med, 7, pp.157~161 (2000)
95. Maimaris C, "Dog-bite lacerations: a controlled trial of primary wound closure", Arch Emerg Med, 5, pp.156~161 (1988)

관련 논문AI추천